AIM: We designed a study to evaluate the cardioprotective effect of two soluble epoxide hydrolase (sEH) inhibitors, 1-(1-propanoylpiperidin-4-yl)-3-(4-trifluoromethoxy)phenyl)urea (TPPU) and trans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]cyclohexyloxy}benzoic acid (t-TUCB), in ischemia-reperfusion (IR) model. METHODS: Cardioprotective effects of the sEH inhibitors were evaluated against IR-induced myocardial damage in hearts from normal, hypertensive, and diabetic rats using Langendorff's apparatus. In addition, the effect of sEH inhibitors on endothelial function was evaluated in vitro and ex vivo using isolated rat thoracic aorta. RESULTS: Ischemia-reperfusion (IR) increased the myocardial damage in hearts from normal rats. IR-induced myocardial damage was augmented in hearts isolated from hypertensive and diabetic rats. Myocardial damage as evident from increase in the activities of lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) in heart perfusate was associated with significant decrease in the heart rate and developed tension, and increase in the resting tension in isolated heart. Both sEH inhibitors protected the heart in normal, hypertensive, and diabetic rats subjected to IR injury. The sEH inhibitor t-TUCB relaxed phenylephrine precontracted aorta from normal rats. Relaxant effect of acetylcholine (ACh) was reduced in aortas from diabetic and hypertensive rats compared to normal rats. Pretreatment of sEH inhibitors to diabetic and hypertensive rats increased relaxant effect of ACh on aortas isolated from these rats. CONCLUSIONS: Prophylactic treatment with sEH inhibitors decreased myocardial damage due to IR, hypertension and diabetes, and decreased endothelial dysfunction created by diabetes and hypertension. Therefore, inhibitors of sEH are useful probes to study cardiovascular pathology, and inhibition of the sEH is a potential approach in the management of IR-induced cardiac damage and endothelial dysfunction-related cardiovascular disorders.
AIM: We designed a study to evaluate the cardioprotective effect of two soluble epoxide hydrolase (sEH) inhibitors, 1-(1-propanoylpiperidin-4-yl)-3-(4-trifluoromethoxy)phenyl)urea (TPPU) and trans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]cyclohexyloxy}benzoic acid (t-TUCB), in ischemia-reperfusion (IR) model. METHODS: Cardioprotective effects of the sEH inhibitors were evaluated against IR-induced myocardial damage in hearts from normal, hypertensive, and diabeticrats using Langendorff's apparatus. In addition, the effect of sEH inhibitors on endothelial function was evaluated in vitro and ex vivo using isolated rat thoracic aorta. RESULTS:Ischemia-reperfusion (IR) increased the myocardial damage in hearts from normal rats. IR-induced myocardial damage was augmented in hearts isolated from hypertensive and diabeticrats. Myocardial damage as evident from increase in the activities of lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) in heart perfusate was associated with significant decrease in the heart rate and developed tension, and increase in the resting tension in isolated heart. Both sEH inhibitors protected the heart in normal, hypertensive, and diabeticrats subjected to IR injury. The sEH inhibitor t-TUCB relaxed phenylephrine precontracted aorta from normal rats. Relaxant effect of acetylcholine (ACh) was reduced in aortas from diabetic and hypertensiverats compared to normal rats. Pretreatment of sEH inhibitors to diabetic and hypertensiverats increased relaxant effect of ACh on aortas isolated from these rats. CONCLUSIONS: Prophylactic treatment with sEH inhibitors decreased myocardial damage due to IR, hypertension and diabetes, and decreased endothelial dysfunction created by diabetes and hypertension. Therefore, inhibitors of sEH are useful probes to study cardiovascular pathology, and inhibition of the sEH is a potential approach in the management of IR-induced cardiac damage and endothelial dysfunction-related cardiovascular disorders.
Authors: John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock Journal: Hypertension Date: 2005-09-12 Impact factor: 10.190
Authors: Todd R Harris; Ahmed Bettaieb; Sean Kodani; Hua Dong; Richard Myers; Nipavan Chiamvimonvat; Fawaz G Haj; Bruce D Hammock Journal: Toxicol Appl Pharmacol Date: 2015-03-28 Impact factor: 4.219
Authors: Jung-Kang Jin; Erik A Blackwood; Khalid Azizi; Donna J Thuerauf; Asal G Fahem; Christoph Hofmann; Randal J Kaufman; Shirin Doroudgar; Christopher C Glembotski Journal: Circ Res Date: 2016-12-08 Impact factor: 17.367
Authors: Abdul Hye Khan; John R Falck; Vijaya L Manthati; William B Campbell; John D Imig Journal: Front Pharmacol Date: 2014-09-23 Impact factor: 5.810
Authors: Justin S Kim; Andres S Arango; Swapnil Shah; William R Arnold; Emad Tajkhorshid; Aditi Das Journal: J Inorg Biochem Date: 2022-01-13 Impact factor: 4.155
Authors: Kin Sing Stephen Lee; Jun Yang; Jun Niu; Connie J Ng; Karen M Wagner; Hua Dong; Sean D Kodani; Debin Wan; Christophe Morisseau; Bruce D Hammock Journal: ACS Cent Sci Date: 2019-09-03 Impact factor: 14.553
Authors: Theresa Aliwarga; Eric A Evangelista; Nona Sotoodehnia; Rozenn N Lemaitre; Rheem A Totah Journal: Int J Mol Sci Date: 2018-06-29 Impact factor: 5.923